ページ3 - トルコで最高のPET-CT検査医師 - トップ63名の医師

Education

• 1986-1989, Bursa High School, Bursa, Turkey
• 1989-1995, Istanbul University, Istanbul School of Medicine, Turkey
• 1999-2003, (Residency) Kadir Has University, School of Medicine, Department of Radiation Oncology, Istanbul, Turkey
• 2015, (Associate Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2021, (Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

Experience

• 1995-1999, Şişli Florence Nightingale Hospital, Istanbul, Cardiology Department
• 2003, Gayrettepe Florence Nightingale Hospital, Istanbul, Department of Radiation Oncology
• 2015, (Associate Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2021, (Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

Education and Specialization

• 2006: Kocaeli University Faculty of Medicine
• 2014: Akdeniz University Faculty of Medicine, Internal Medicine
• 2018: Akdeniz University Faculty of Medicine, Medical Oncology

Experience

• 2006 - 2008: Konya Derebucak District Hospital
• 2009 - 2015: Akdeniz University Hospital
• 2015: Antalya Kaş State Hospital
• 2015 - 2016: İnönü University Faculty of Medicine
• 2016 - 2021: Akdeniz University Hospital
• 2021 - 2023: Antalya Training and Research Hospital

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Academic Details

Faculty / University
19 Mayis University, Faculty of Medicine, Samsun – Turkey

Date of Graduation
1992

Postgraduate Training
Institution: Department of Radiology, Faculty of Medicine, Erciyes University, Kayseri – Turkey
Supervisor in Charge of Training: Mustafa Ozturk
Training Period: From 1993 to 1998
Title of Thesis: Evaluation of Lower Extremity Artery-Occlusive Disease by MR Angiography

Accreditation

Radiology Specialist: 1998, The Ministry of Health of Turkey

Associate Professor: 2003, Interuniversity Committee

Academic Experience

Residency: Department of Radiology, Erciyes University, Kayseri – Turkey (1993 to 1998)

Private Practice: Maternal and Children Hospital, Sivas – Turkey (1998–2000)

Academic Positions:

2000 to 2003: Assistant Professor of Radiology, Firat University, Elazig – Turkey

2003 to 2009: Associate Professor of Radiology, Firat University, Elazig – Turkey

2009 to 2010: Professor of Radiology, Firat University, Elazig – Turkey

2010 to 2015: Professor of Radiology, Chairman, Bezmialem Vakif University, Istanbul – Turkey

2015 to 2016: Professor of Radiology, Chairman, Yeditepe University, Istanbul – Turkey

2017 to Present: Professor of Radiology, Interventional Radiology Unit, Bahçelievler Medical Park Hospital, Altınbaş University, Istanbul – Turkey

Fellowship

Institution: Department of Radiology, University Hospital of Cleveland, Case Western Reserve University, Cleveland, Ohio, USA

Duration:  2004 to 2005

Position: Research Fellow – Ultrasound & CT (Body)

Professional Memberships

-Turkish Society of Radiology

-Medical Ultrasound Society of Turkey

-Turkish Society of Radiology, Abdominal Radiology Study Group

-ESGAR – European Society of Gastrointestinal and Abdominal Radiology (Fellow)

-ESUR – European Society of Urogenital Radiology (Fellow)

-ESR – European Society of Radiology

-Turkish Society of Magnetic Resonance

-Turkish Society of Radiology, Urogenital Radiology Study Group

-Turkish Society of Interventional Radiology

-Korean Society of Radiology (International Member)

-Radiological Society of North America (RSNA) – Corresponding Member

Prizes and Awards

European Congress of Radiology (ECR) 2002, Vienna – Image Interpretation, 3rd Prize

Interpretation Corner of European Radiology 2003 – 2nd Prize

Cases of the Day – ESGAR 2007, Lisbon, Portugal – 2nd Prize

Cases of the Day – ESGAR 2009, Valencia, Spain – 1st Prize

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Assoc. Prof. Dr. Mehmet Salih İyikesici is a medical oncologist. He provides personalized care for breast, lung, and gastrointestinal cancers. He combines metabolically supported therapies with chemotherapy. His interests include the ketogenic diet in cancer care, hyperthermia, and hyperbaric oxygen therapy.

He has conducted and contributed to national and international scientific studies. Selected national peer-reviewed publications include Metabolic Supported Chemotherapy in Rectal Cancer (2020), NSCLC Patient Outcomes – Marmara University (2004), and Early-Stage Breast Cancer Outcomes (2004).

2017: Oticon Medical Scientific Center Copenhagen Denmark.
2016: ICLO Teaching Center New Endoscopic Approaches to Lateral Skull Base, Inner Ear and Cerebello-Pontine Angle, Verona Italy
2016: World Hearing Center, Institute of Physiology and Pathology of Hearing, Warsaw,Poland
2015: Cochlear Science and Research Center Berlin Germany.
2014: Cochlear implant Center Medel Company Innsburck, Austria.
2014: Hannover Medical School. Clinic for Laryngology, Rhinology and Otology, Hannover, Germany
2014: Academy of Hearing Aid Acoustics (Akademie für Hörgerate-Akustik), Lübeck, Germany.
2013: International European Sialendoscopy Training Center, Geneva, Switzerland.
2012: University clinic of ORL, Head and Neck Surgery, klinikum der Universitat, Munchen, Germany.
2012: University clinic of ORL, Head and Neck Surgery, Bern, Switzerland.
2011: University clinic of ORL, Head and Neck Surgery, klinikum der Universitat, Munchen, Germany.
2007: The Ohio State University, Medical Faculty, Department of Otolaryngology, Division of Otology and Neurotology. Columbus, Ohio, USA.
2006: University of Würzburg, Department of Otolaryngology, Division of Otology and Neurotology. Würzburg, Germany.
1999-2003 İnönü Üniversitesi Tıp Fakültesi Kulak Burun Boğaz Anabilim Dalı
1993-1999 İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi

Turkish Otorhinolaryngology and Head and Neck Surgery Association

Turkish Otorhinolaryngology and Head and Neck Surgery Foundation

Turkish Rhinology Society

Tigris-Euphrates Basin Otorhinolaryngology and Head and Neck Surgery Association

Gaziantep Otorhinolaryngology Association

Turkish Otorhinolaryngology and Head and Neck Surgery Qualification Board

Turkish Otology Association

Malatya Otorhinolaryngology Association

American Academy of Otolaryngology Head and Neck Surgery

Mediterranean Society of Otology and Audiology

International Vertigo Association

この医師は、放射線学、インターベンショナルラジオロジー、肥満治療、インターベンショナルオンコロジーの分野で尊敬される権威です。患者ケアの改善に対する彼らの献身は、医療文献への多くの貢献を通じて明らかであり、さまざまな医療状態の理解と治療に大きな影響を与えています。<\/p>

イスタンブール大学、Cerrahpaşa医学部を卒業した後、医師はMemorial Sloan Kettering Cancer Centerで放射線学のレジデンシーとインターベンショナルラジオロジーのフェローシップを修了しました。彼らの研究は、COVID-19患者の死後の生検や革新的な癌治療などのトピックをカバーしており、著名なジャーナルに発表されています。<\/p>

Education

Cumhuriyet University Faculty of Medicine, 2004
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine Residency, 2010
Karadeniz Technical University Faculty of Medicine Medical Oncology Residency, 2015

Experience

MD Andeson Cancer Center, USA, 2008
Sunnybrook Odette Cancer Center Breast Cancer Clinic, Canada, 2017
Moffit Cancer Center , USA 2022
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine, 2010
İdil State Hospital Internal Medicine Clinic, 2011
Karadeniz Technical Universityniversitesi Faculty of Medicine, Medical Oncology Clinic, 2015
Istanbul Göztepe Training and Research Hospital, Medical Oncology Clinic, 2018
Yeniyüzyıl University Gaziosmanpaşa Hospital, Medical Oncology Clinic, 2020
Ataşehir Medicana Hospital, Medical Oncology Clinic, 2022

Scientific Membership

Turkish Medical Association (TTB)
Turkish Society of Medical Oncology (TTOD)
European Society for Medical Oncology (ESMO)
American Society of Medical Oncology (ASCO)

Medical Intrests

• Breast Cancer
• Lung Cancer
• Colon Cancer
• Stomach Cancer
• Rectal Cancer
• Ovarian Cancer
• Liver Cancer
• Oesophageal Cancer - Oesophageal Cancer
• Kidney Cancer
• Larynx Cancer - Cancer of the Larynx
• Thyroid Cancer
• Head and Neck Cancers
• Gynaecological Cancers
• Pancreatic Cancer
• Oesophageal Cancer - Oesophageal Cancer
• Uterine Cancer
• Brain Cancers - Brain Tumours
• Soft Tissue Cancer - Sarcomas
• Prostate Cancer
• Bladder Cancer
• Bile Tract Cancer
• Testicular Cancer
• Cervical Cancer
• Mouth, Tongue, Lip Cancers
• Gastrointestinal System Cancers
• Bone Tumours
• Trachea and Bronchial Cancers
• Skin Cancers - Skin Cancers
• Skeletal System Tumours
• Gallbladder Cancer
• Mesothelioma

Education

Istanbul University Cerrahpaşa Faculty of Medicine, 2002
Istanbul Fatih Sultan Mehmet Training and Research Hospital, Internal Medicine, 2010
Istanbul University Oncology Institute (Çapa), Medical Oncology, 2015
Medipol University Faculty of Medicine, Phytotherapy Education, 2018
University of Health Sciences, Vocational School of Health, Molecular Oncology, PhD Program, PhD, 2023

Experience

University Hospital, Newark, New Jersey, USA, Observer (2003-2004)
Siirt State Hospital, Internal Medicine (2010-2011)
Siirt State Hospital, Medical Oncology (2015)
Bakırköy Dr. Sadi Konuk Training and Research Hospital, Medical Oncology (2015-2018)
Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Medical Oncology, (Professor Doctor) (2018-Present)
Forensic Medicine 3. Specialization Board, Medical Oncology, Full Member (2019-Present)
Liv Hospital, Ulus, Park-time, Medical Oncology (2020-2022)
Şişli Kolan International Hospital, Park-time, Medical Oncology (2022-2023)

Medical Intrests

• Gastrointestinal System Tumours (Esophagus - Stomach and Large Bowel Cancer)
• Hepatobiliary System Tumours (Liver-Biliary Tract and Pancreatic Cancer)
• Breast Cancer
• Lung Cancer
• Genitourinary Cancers
• Immunotherapies and Target Therapies
• Molecular Oncology
• Immunotherapies
• Target Treatments
•  

Awards

2010-YDUS (Subspecialty Examination) 14th place in Turkey
2014- Oncology Institute Days Best Poster Award
2015- Turkish Medical Oncology Society Board Exam Qualification
2015- ESMO (European Society for Medical Oncology) Board Exam Qualification

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Medical Field of Special Interest and Activities 

Molecular Scanning 

Nuclear Oncology 

Radionuclide Treatments

Education and Experience 

2018 - Private LIV Hospital Ulus 

2015 - 2018 İstanbul Bilim University, Şişli Florence Nightingale Hospital 

2006 - 2015 Mersin University Master of Science in Nuclear Medicine 

2005 - 2006 Ankara Özel Denge Medical Centre 

2004 Hacettepe University Medical Faculty 

Specialization Training: 2000 - 2004 Hacettepe University Master of Science in Nuclear Medicine 

Undergraduate: 1993 - 1999 Hacettepe University Medical Faculty

Memberships 

Journal of Musculoskeletal Pain 

Turkish Journal of Clinical Sciences 

Molecular Imaging and Radionuclide Therapy 

Turkish Clinics Journal of Case Reports 

Journal of Clinical and Experimental Investigations 

Journal of Clinical and Analytical Medicine 

Acıbadem University Health Sciences Magazine 

Turkey Nuclear Medicine Association

Researches and Publications 

International Article: 35

Domestic Article: 18 

Chapter Author: 5 

Member of Broadcasting Advisory Board: 7 Domestic-International Magazines 

Internalnational Conference Presentations: 22

Education

• Faculty of Medicine: Trakya University, 1982-1988
• Radiation Oncology Residency: Şişli Etfal Training and Research Hospital, 1994-1998
• Radiation Oncology Residency: Princess Margaret Hospital Toronto, 1996
• Phytotherapy Master's Degree: Istanbul University Faculty of Pharmacy, 2017-2018

Experience

• Professor, Head of Department: Health Sciences University Bursa Faculty of Medicine, Department of Radiation Oncology, 2021-2024
• Professor, Head of Department: Health Sciences University Izmir Faculty of Medicine, Department of Radiation Oncology, 2021-2024
• Professor: Department of Radiation Oncology, Health Sciences University Istanbul Hamidiye Faculty of Medicine, 2021-2024
• Lecturer Gelisim University SMYO, 2013-2020

Medical Interests

• Breast Cancer / Intraoperative Radiotherapy
• Gynaecological Cancers / Brachytherapy Applications
• Gastrointestinal System Tumours
• Prostate Cancer / Hydrogel Space Oar Certificate and Application
• Lung Cancers
• Brain Tumours
• Head and Neck Cancers

Marmara University Faculty of Medicine, Department of Radiation Oncology Specialization training: 2012 -2016

Marmara University Faculty of Medicine (English) Undergraduate: 2004-2011

Sixteen Numbered Shirvan School (Azerbaijan) High School: 1998 -2004

Medical Interests and Activities 

• Gastrointestinal diseases 

• Oncologic laparoscopic surgery 

• Anorectal area diseases 

• Urgent surgical cases (acute cholecystitis, divertikülit, ileus, pankreatit, appendicitis) 

• Colon and rectum cancer 

• Treatment of oncologic surgical cases with further laparoscopic and robotic surgery. • Laparoskopik hernia surgery 

• Esophagus and stomach cancer 

• Selim anorectal diseases (hemorrhoidal disease, anal fissure), perianal fistula, pilonoidal sinus (hairless- non-surgical treatment)

Education and Experience 

• İstanbul University Medical Faculty 1988 • University of Colorado Health Science Center – Intern Surgeon 

• Isparta, Dedeçam Şehit Ramazan Karaca Health Center (1995-1996) • İstanbul Surgery Hospital – American Hospital (2000-2001) 

• Chief assistant Istanbul Medical Faculty, Department of General Surgery (2001-2008) • World Congress on Peritonel Surface Malignancies (HIPEC course) Berlin, Germany (2012) 

• USC Keck School of Medicine, Los Angeles, CA, USA (2006-2007) 

• Assoc. Prof. M.D. , İstanbul Medical Faculty General Surgery (2008-2014) 

• Da Vinci Robotic Intensive Course at IRCAD, Strasbourg, France (2011) 

• Stony Brook Medicine Cadaver Training Event in Colon and Rectal Surgery, New York, USA (2016) (Instructor) 

• Fellow of the European Board of Surgery- Emergency Surgery (FEBS EmSurg) Honorary Diploma (2017) 

• Prof. M.D. , İstanbul Medical Faculty General Surgery (2014 -2017) 

• İstanbul University Medical Faculty – General Surgery Master of Science 1996 

• University of Southern California Medical Center, Department of General Surgery, Los Angeles, USA – February 2006 – February 2007

Scientific Publications • Endoscopic Laparoscopic & Minimal Invasive Surgery Journal Editorial Board / National Scientific Committee • UTACD Assist. Editor

Areas of Interests

• MR Linac
• Three Dimensional Brachytherapy
• Four Dimensional (4D) Radiotherapy
• Stereotactic RT & IMRT
• Breast Cancer, Gynecological Cancers
• Head – Neck Cancers
• Urological Tumors, Gastrointestinal Cancers
• Lung Cancer
• Central Nervous System Tumors & Metastases
• Skin Cancers
• Soft Tissue Tumors

Education:

• Istinye University Medical Faculty, Professor Doctor (2017 – Continued)
• Istine University Medical Faculty Associate Professor Doctor (2016 – 2017)
• Liv Hospital Radiation Medicine Center, Tbilisi, Georgia, Radiation Oncology Consulting Docor (2016 – 2019)
• Liv Hospital, Radiation Oncology (2015 – Continued)
• Istanbul University Oncology Institution, Associate Professor (2012 – 2015)
• Stereotactic Radiotherapy, Thoracic Oncology, University of North Carolina, NC, USA (2010 – 2011)
• Kocaeli University Radiation Oncology Department, Associate Professor Assistant (2006 – 2009)
• GATA Radiation Oncology Department, Specialist Doctor, Reserve Officer (2004 – 2005)
• Istanbul University, Medical Faculty, Dr.R.A. (1999 – 2004)
• Istanbul University, Medical Faculty, Under-Graduate (1993 – 1999)
   

Experience:

• Istinye University Medical Faculty
• Liv Hospital Ulus
• Istanbul University Oncology Institution
• University of North Carolina, NC, USA
• Kocaeli University Medical Faculty
• Istanbul University, Medical Faculty

専門分野：

• 陰茎プロテーゼ
• 膀胱がん
• 前立腺がん
• 腎臓がん（根治的部分的腎切除術）
• 腹腔鏡下泌尿器科
• 腎結石
• 女性の尿失禁手術
• 尿道下裂手術
• 小児膀胱尿管逆流
• 顕微鏡的静脈瘤手術
• 陰茎増大手術
• ペイロニー病および陰茎湾曲手術

特定の手順：

• 陰茎プロテーゼ手術
• 泌尿器腫瘍学および腹腔鏡手術

経験：

• イスタンブール大学医学部、泌尿器科研修プログラム（2002-2008）
• ハセキ教育研究病院（2009-2011）
• ベズミアレム・ワクフ大学（2011-2016）
• メディカルパーク バフチェリエブレル（2016）
• エティカ インシルリ病院（2016-2018）
• メディカーナ病院バフチェリエブレル、泌尿器科部、医学博士、医学教授（2018-現在）

Prof. graduated from Izmir Eşrefpaşa High School in 1996. Dr. Serdar KALEMCİ graduated from Süleyman Demirel University Faculty of Medicine in 2003. In 2009, he specialized in Dokuz Eylül University Faculty of Medicine, Department of Chest Diseases. He completed his compulsory service at Şanlıurfa Suruç State Hospital in 2010.

In 2015, he received the title of associate professor while working at Muğla University Faculty of Medicine, Department of Chest Diseases. Kalemci has clinical and experimental studies in the field of Chest Diseases.

He has 50 international publications. 4 of these were published in SCI and 36 in SCI EXPANDED journals. He has 20 national publications. He has made oral and written presentations at many national and international congresses.

He is Ear – Nose – Throat and Head and Neck Surgery Specialist. In 1974 he graduated from Ankara Ataturk High School. After he finished preparatory class in English for 1 year in ODTU, he won Hacettepe University Eskisehir Medical Faculty.

In 1980 he finished Hacettepe University Eskisehir Medial Faculty. In 1984 he got his career education in the department of ENT in Hacettepe University Medical Center. He served his military service in Ankara Mevki Hastanesi as an ENT Specialist, in 1986 he began his conscription in state of Ordu Government Hospital.

He worked in Izmir Atatürk Education and Research Hospital as chief intern in 1989, as a chef assistant in 1991, as an instructor in 1994 and worked there till June 2008. On June 20088, he worked in Namik Kemal University Medical Faculty in head of the department of ENT, Head of Department of Surgical Medical and worked as a Medical Faculty member of University Senate finally, he resigned on August in 2010.